Abstracts tagged "anti-TNF therapy"

Abstract Number: 467 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Rabbit Risk Score for Serious Infections in a UK Anti-TNF Treatment Cohort
Lucia Silva-Fernandez^1,2, Mark Lunt¹, Kath D. Watson¹, . BSRBR Control Centre Consortium¹, Deborah P. Symmons¹, Kimme Hyrich¹ and . On behalf of the BSRBR³, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Rheumatology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³British Society for Rheumatology, London, United Kingdom
Background/Purpose: Serious infections (SI) are a major concern in patients treated with tumour necrosis factor inhibitors (TNFi). The RABBIT Risk Score (RRS) (1) allows a…
Abstract Number: 2134 • 2014 ACR/ARHP Annual Meeting
Baseline Scintigraphic Detection of TNFá As a Predictor of Therapy Response after Treatment with Certolizumab Pegol in Rheumatoid Arthritis and Spondyloarthritis Patients
Philippe Carron¹, Bieke Lambert², Filip De Vos³, Gust Verbruggen¹, Dirk Elewaut¹ and Filip van Den Bosch¹, ¹Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ²Department of Nuclear Medicine Ghent University Hospital, Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium, ³Radiopharmacy, Department of Radiopharmacy Ghent University, Ghent, Belgium
Background/Purpose: A major challenge in the biologic era is to predict clinical response. A large variability in the level of TNFα expression has been recognized…
Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Layla Saliba¹, Guillaume Moulis², Malak Aboutaam³, Grégory Pugnet², Vanessa Rousseau¹, Leila Chebane¹, Nadine Petitpain⁴, Bernadette Baldin⁵, Jean-Louis Montastruc¹ and Haleh Bagheri¹, ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, ²Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, ⁴Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, ⁵Nice University Hospital, Pharmacovigilance Regional Center, Nice, France
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…
Abstract Number: 466 • 2014 ACR/ARHP Annual Meeting
Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery?
Charlotte Mabille¹, Adeline Ruyssen Witrand², Thomas Barnetche^3,4, Arnaud Constantin⁵ and Alain G. Cantagrel⁵, ¹Rheumatology Unit, hopital Purpan, Toulouse, France, ²Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ³rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁴Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁵Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose Anti-TNFs have greatly contributed to improve RA prognosis. Hence, the needs for orthopedic surgery have considerably decreased in the past years. However, surgery, whether…
Abstract Number: 2966 • 2014 ACR/ARHP Annual Meeting
Genome-Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Marieke J.H. Coenen¹, Maša Umicevic-Mirkov¹, Sophine B. Krintel², Julia Johansen³, Corinne Miceli-Richard⁴, Henrik Kallberg⁵, Hans Scheffer¹, Wietske Kievit¹, Mart A. van de Laar⁶, Piet L.C.M. van Riel¹, X. Mariette⁷, Saedis Saevarsdottir⁸, Merete Lund Hetland⁹, Sita Vermeulen¹ and Cornelis A. Albers¹, ¹Radboud university medical center, Nijmegen, Netherlands, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Department of Medicine, Herlev, University of Copenhagen, Frederiksberg, Denmark, ⁴Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶University Twente & Medisch Spectrum Twente, Enschede, Netherlands, ⁷Paris-Sud University, Paris, France, ⁸Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁹DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
Background/Purpose: Pain is the dominant and prevailing symptom of rheumatoid arthritis (RA). Tumor necrosis factor inihibitors (TNFi) have proven very successful in pain reduction. Interestingly,…
Abstract Number: 2096 • 2014 ACR/ARHP Annual Meeting
Assessment of RA Heterogeneity in Two Independent Cohorts of Patients
Joshua Joung, Yauheniya Cherkas and Sarah Lamberth, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose RA is known to be a heterogeneous disease, with heterogeneity existing in both clinical symptoms and responses to therapies. Molecular assessment of this heterogeneity…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…
Abstract Number: 464 • 2014 ACR/ARHP Annual Meeting
Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease
Boulos Haraoui¹, Vivian P. Bykerk², Ronald van Vollenhoven³, Marc de Longueville⁴, Kristel Luijtens⁵, Pauline Ralston⁶ and Arthur Kavanaugh⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴SA Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Giant Professional Ltd, London, United Kingdom, ⁷University of California San Diego, La Jolla, CA
Background/Purpose Certolizumab pegol (CZP) is approved for adult patients (pts) with rheumatic diseases (RA, PsA and AS) at a maintenance dose of 200mg every 2…
Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Paz Rodríguez-Cundín², Emma Beltrán³, Juan Sánchez Bursón Sr.⁴, Marina Mesquida⁵, Alfredo Adan⁵, M. Victoria Hernández⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², Jose Luis García Serrano¹³, Norberto Ortego-Centeno¹⁴, Jose M Herreras¹⁵, Alejandro Fonollosa¹⁶, Angel M. Garcia-Aparicio¹⁷, Olga Maiz Alonso¹⁸, Ana Blanco¹⁹, Ignacio Torre Salaberri²⁰, Cruz Fernández- Espartero²¹, Vega Jovani²², Diana Peiteado²³, Esperanza Pato²⁴, Juan Cruz²⁵, Carlos Férnandez Cid²⁶, Elena Aurrecoechea²⁷, Miriam García-Arias²⁸, Miguel Angel Caracuel-Ruiz²⁹, Carlos Alberto Montilla Morales³⁰, Antonio Atanes-Sandoval³¹, Félix Francisco³², Santos Insua³³, Senen González-Suárez³⁴, Maria Amalia Sanchez Andrade³⁵, Fernando Gamero³⁶, Luis Francisco Linares Ferrando³⁷, Fredeswinda Romero³⁸, A. Javier García-González³⁹, Raquel Almodóvar González⁴⁰, Enrique Minguez⁴¹, Carmen Carrasco Cubero⁴², Alejandro Olive⁴³, Julio Vázquez⁴⁴, Oscar Ruiz Moreno⁴⁵, Fernando Jiménez-Zorzo⁴⁵, Javier Manero⁴⁵, Santiago MuÑoz Fernandez⁴⁶, Javier Rueda-Gotor¹, Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Rheumatology. Hospital de Valme., Sevilla, Spain, ⁵Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁷Ophthalmology. Hospital General universitario de Valencia, Valencia, Spain, ⁸Rheumatology. Hospital Peset, Valencia, Spain, ⁹Ophthalmology. Hospital Peset, Valencia, Spain, ¹⁰H. Vall d'Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Ophthalmology. Hospital San Cecilio, Granada, Spain, ¹⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁵Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, ¹⁶Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁷Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ¹⁸Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁹Ophthalmology. Hospital Donosti, San Sebastián, Spain, ²⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ²¹Rheumatology, Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, ²²Rheumatology. Hospital General de Alicante, Alicante, Spain, ²³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²⁴Rheumatology. Hospital Clínico San Carlos, Madrid, Spain, ²⁵Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, ²⁶Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, ²⁷Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁸Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁹Plaza Cruz Roja, 1, H. Reina Sofia, Cordoba, Spain, ³⁰Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³¹Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ³²Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ³³Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, ³⁴Rheumatology. Hospital Cabueñes, Gijón, Spain, ³⁵Hosp. Lucus Augusti, Lugo, Spain, ³⁶Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, ³⁷Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³⁸Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³⁹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴¹Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology, Hospital de Merida, Mérida, Spain, ⁴³Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ⁴⁴Rheumatology. Hospital de Ferrol, A Coruña, Spain, ⁴⁵Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ⁴⁶Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…
Abstract Number: 2092 • 2014 ACR/ARHP Annual Meeting
Proteomic Phenotyping of Rheumatoid Arthritis Disease Activity
Yauheniya Cherkas, Sarah Lamberth, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose The use of objective biomarkers of clinical disease characteristics such as disease activity would be beneficial in informing patients, physicians and payers. Recently, a…
Abstract Number: 825 • 2014 ACR/ARHP Annual Meeting
Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
Elizabeth V. Arkema¹, Johan Askling² and the ARTIS Study group³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: The rheumatoid arthritis (RA) population starting tumor necrosis factor inhibitors (TNFi) today is much different in terms of accumulated and concurrent disease activity and…
Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay¹, Roy Fleischmann², Edward C. Keystone³, Elizabeth C. Hsia^4,5, Neil Goldstein⁴, Benjamin Hsu⁴, Yiying Zhou⁴, Jürgen Braun⁶ and Arthur Kavanaugh⁷, ¹UMass Memorial Medical Center, Worcester, MA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷University of California San Diego, La Jolla, CA
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…
Abstract Number: 2811 • 2014 ACR/ARHP Annual Meeting
Improvements in Rheumatoid Arthritis Related Fatigue Are Driven By Reductions in Pain, Not Disease Activity – Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Katie L Druce¹, Gareth T Jones², Gary J. Macfarlane¹ and Neil Basu¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Musculoskeletal Research Collaboration (Epidemiology Group),, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients commonly report reductions in fatigue after commencing Anti-TNF therapy. The mechanisms behind such reductions have not been determined, although it…
Abstract Number: 2086 • 2014 ACR/ARHP Annual Meeting
Replication of PTPRC As Genetic Biomarker of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis
Antonio Gonzalez¹, Aida Ferreiro-Iglesias², Juan Gomez-Reino³ and on Behalf of Their Collaborators⁴, ¹Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Insitituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁴multiple, multiple, Spain
Background/Purpose The use of biomarkers to predict response to the different drugs available for treating rheumatoid arthritis (RA) is a very desirable goal. However, success…
Abstract Number: 823 • 2014 ACR/ARHP Annual Meeting
Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol
Alina Soare¹, Carina Mihai², Ana Maria Gherghe², Rucsandra Dobrota², Raida Oneata², Simona Pintilie², Mihaela Milicescu², Ioan Ancuta², Andrei Martin², Mariana Sasu², Claudia Ciofu², Liviu Macovei², Victor Stoica² and Mihai Bojinca², ¹internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania
Background/Purpose Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi), especially in countries with a high TB burden. Careful TB screening is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].